SCHEMBL23600366

SCHEMBL23600366

O=C1NC(=O)/C(=C/c2c[nH]c3ccncc23)N1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CGAS Q8N884 1/20 0.51
KDM4E B2RXH2 4/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
PKM P14618 1/20 0.44
MAPT P10636 2/20 0.38
HTR6 P50406 1/20 0.38
LMNA P02545 1/20 0.38
RAB9A P51151 1/20 0.38
CCNT1 O60563 1/20 0.38
CDK9 P50750 1/20 0.38
HASPIN Q8TF76 1/20 0.38
GSK3B P49841 4/20 0.38
KDR P35968 2/20 0.37
FLT3 P36888 2/20 0.37
POLB P06746 1/20 0.37
NCOA1 Q15788 1/20 0.37
NCOA3 Q9Y6Q9 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29764637 1.00 CGAS (0.51) CGASKDM4EALDH1A1HPGDPKM
SCHEMBL23600353 0.89 CGAS (0.51) CGASKDM4EALDH1A1HPGDPKM
SCHEMBL3467529 0.80 NTRK1 (0.56) KDM4EALDH1A1HPGDMAPTLMNA
SCHEMBL3467353 0.80 NTRK1 (0.56) KDM4EALDH1A1HPGDMAPTLMNA
SCHEMBL3467350 0.80 NTRK1 (0.56) KDM4EALDH1A1HPGDMAPTLMNA
SCHEMBL23600439 0.77 PIM1 (0.39) KDM4EALDH1A1MAPTHTR6RAB9A
SCHEMBL29764599 0.77 PIM1 (0.39) KDM4EALDH1A1MAPTHTR6RAB9A
SCHEMBL23582847 0.77 PIM1 (0.38) KDM4EALDH1A1HPGDMAPTHTR6
SCHEMBL23600201 0.76 PIM1 (0.43) KDM4EHTR6RAB9ACCNT1CDK9
SCHEMBL29764697 0.76 PIM1 (0.43) KDM4EHTR6RAB9ACCNT1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-04-27 US disclosed
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-04-27 US disclosed
EP-4083037-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME Yonsei University, University-Industry Foundation(UIF). (KR) 2022-11-02 EP disclosed
WO-2021133037-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME 연세대학교 산학협력단 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME MAPT, APP, PRNP CGAS 2700/4885KDM4E 3638/4885ALDH1A1 4631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.